Benefit-Risk in the PBRER: Writing the Integrated Evaluation That Reviewers Actually Read

The benefit-risk evaluation is the part of a periodic report where a company states its view of the product. ICH E2C(R2) asks for it to be integrated and reasoned, yet many reports still repeat safety data and leave the conclusion implicit.

How the guideline structures the evaluation

ICH E2C(R2) builds the evaluation from linked sections. Risk is characterised in section 16, benefit in section 17, and the two are brought together in the integrated benefit-risk analysis in section 18. Section 19 then states conclusions and any actions that follow.

  • Benefit (section 17): baseline efficacy at the start of the interval, new information on efficacy and effectiveness, and a critical characterisation covering the strength of evidence, effect size, clinical relevance and generalisability.
  • Risk (section 16): closed signals, new information on known risks, characterisation of important risks using cumulative data, and the effectiveness of risk minimisation measures.
  • Integration (section 18): the medical need and available alternatives, then the benefit-risk balance for each indication and, where profiles differ, by population.

What a good section 18 does

The guideline expects a clear rationale rather than a prescribed quantitative model. The authors identify the key benefits and risks, consider the treatment context and the uncertainty in the evidence, and explain how they weighed them. If a formal quantitative or semi-quantitative method is used, its methods should be summarised. Economic considerations are outside the scope.

Importantly, the evaluation sections are meant to interpret, not restate. Section 18 should integrate what was said earlier rather than copy it.

Proportionality

Depth should match the importance of the new information. When there is important new information or an ad hoc request, a detailed analysis is expected. Otherwise the analysis can focus mainly on the safety data of the interval, provided the conclusion is still explicit.

Typical weaknesses

  • A conclusion that says the balance remains favourable without saying why.
  • Benefit sections that ignore real-world effectiveness data or new indications approved during the interval.
  • Risk sections that never connect to the effectiveness of risk minimisation measures.
  • No link from section 19 to proposed changes in the reference product information or the risk management plan.
  • Different authors for benefit and risk with no one accountable for the integrated view.

Consistency across the lifecycle

The benefit-risk reasoning should be traceable from the risk management plan, through the periodic report, to any signal assessment or variation. Regulators compare these documents, and unexplained shifts in tone or conclusion invite questions.

How PQRA helps

PQRA can review benefit-risk sections of periodic reports, help structure the argument and the evidence behind it, and check consistency with the risk management plan and product information. We can also support teams that are moving from a PSUR habit to a more reasoned PBRER style.

Contact PQRA to discuss your periodic benefit-risk evaluations.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *